| Nov 27 2024 |
FDA Affirms Its Decision to Remove 25 Plasticizers From the Food Additive Regulations |
K&L Gates LLP |
| Nov 27 2024 |
Take a Sad Song and Make It Better: Fifth Circuit’s Commercial Speech Ruling Leaves Door Open to State Law Challenge |
Bradley Arant Boult Cummings LLP |
| Nov 27 2024 |
Briefing Continues in Lawsuit Targeting Florida Cultivated Meat Ban |
Keller and Heckman LLP |
| Nov 27 2024 |
Relaxation of Long-Standing Restrictions on Foreign Investment in the Healthcare Sector in China |
McDermott Will & Emery |
| Nov 26 2024 |
Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescriptions of Controlled Medications |
Norris McLaughlin P.A. |
| Nov 26 2024 |
9th Circuit Finds ‘Fruit Naturals’ Label Not Deceptive |
Keller and Heckman LLP |
| Nov 26 2024 |
New Jersey General Assembly Passes Legislation Prohibiting Sale of Diet Pills, Weight Loss/Muscle Building Supplements to Minors |
Epstein Becker & Green, P.C. |
| Nov 25 2024 |
Putting the Uniformity Back in the Uniform Trade Secrets Act: Sixth Circuit Rules Breach of Contract Claims Can Still Be Used to Protect Trade Secrets |
Foley & Lardner LLP |
| Nov 23 2024 |
FDA Extends Comment Deadline for Proposed Post-Market Assessment Approach |
Keller and Heckman LLP |
| Nov 22 2024 |
EPA Releases Updates to Suggested Pesticide Benefits Information Submittals |
Bergeson & Campbell, P.C. |
| Nov 22 2024 |
McDermott+ Check-Up: November 22, 2024 |
McDermott Will & Emery |
| Nov 22 2024 |
Gaetz Out as Possible Attorney General, Pam Bondi New Nominee: A Discussion Still Limited to Cannabis Implications |
Bradley Arant Boult Cummings LLP |
| Nov 22 2024 |
PBM Policy and Legislative Update — Fall 2024 |
Mintz |
| Nov 22 2024 |
CLP Amendment and Updated CLP Guidance Published (Highly Relevant to Endocrine Disruptors) |
Keller and Heckman LLP |
| Nov 22 2024 |
Owner, Operator of Texas Lab Charged for $79 Million Medical Testing Fraud Scheme |
ArentFox Schiff LLP |
| Nov 21 2024 |
October 2024 Bounty Hunter Plaintiff Claims |
Keller and Heckman LLP |
| Nov 21 2024 |
Raising Capital in the Cannabis Business: Pitfalls and Possibilities |
Bradley Arant Boult Cummings LLP |
| Nov 21 2024 |
The 2025 Final Hospital Outpatient Prospective Payment System and Physician Fee Schedule Rules: What Pharma Stakeholders Need to Know |
ArentFox Schiff LLP |
| Nov 20 2024 |
Biomanufacturing Interagency Working Group Identifies Actions to Increase U.S. Biomanufacturing Capacity |
Bergeson & Campbell, P.C. |
| Nov 20 2024 |
California Department of Public Health Rejects Petition Requesting Synthetic Dye Warnings |
Keller and Heckman LLP |
| Nov 20 2024 |
Matt Gaetz Nominated as Attorney General: A Discussion Limited to Cannabis Implications |
Bradley Arant Boult Cummings LLP |
| Nov 20 2024 |
FDA Clinical Investigations: New Guidance on Electronic Systems |
Foley & Lardner LLP |
| Nov 20 2024 |
California Ballot Proposition 34 Targets Spending by Certain 340B Covered Entities |
McDermott Will & Emery |
| Nov 19 2024 |
PA Department of Revenue Not Ready to Double Tax Ready to Drink Cocktails |
Norris McLaughlin P.A. |
| Nov 19 2024 |
Unpacking Johnson & Johnson’s Lawsuit Over 340B Rebate Model |
Mintz |
| Nov 19 2024 |
FDA Requests Information on PFAS in Seafood |
Keller and Heckman LLP |
| Nov 19 2024 |
Trending in Telehealth: October 29 – November 11, 2024 |
McDermott Will & Emery |
| Nov 18 2024 |
Still in Telemedicine Limbo: DEA Issues Third Temporary Rule Extending Controlled Substance Prescribing Flexibilities Through December 2025 |
Polsinelli PC |
| Nov 18 2024 |
DEA Extends Telehealth Lifeline for Patients |
Robinson & Cole LLP |
| Nov 18 2024 |
DEA Issues Third Extension to Public Health Emergency Telemedicine Prescribing Flexibilities, Through 2025 |
Epstein Becker & Green, P.C. |
| Nov 18 2024 |
AAFCO Seeks Public Feedback on Proposed New Additions to the Common Food Index |
Keller and Heckman LLP |
| Nov 18 2024 |
New DEA Rule Extends Controlled Substance Telemedicine Prescribing Flexibilities One More Year |
Foley & Lardner LLP |
| Nov 18 2024 |
DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 |
McDermott Will & Emery |
| Nov 18 2024 |
DEA Extends COVID-19 Telemedicine Prescribing Flexibilities a Third Time |
Robinson & Cole LLP |
| Nov 18 2024 |
Pair of First Circuit Cases Give Court Opportunities for Recognizing Scope of Federal Authority to Regulate Marijuana Businesses |
Bradley Arant Boult Cummings LLP |
